ADEZMAPIMOD

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H16FN3OS
Molecular Weight	377.435
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C[S+]([O-])C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(F)C=C4

InChI

InChIKey=CDMGBJANTYXAIV-UHFFFAOYSA-N

InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)

HIDE SMILES / InChI

Molecular Formula	C21H16FN3OS
Molecular Weight	377.435
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

SB-203580 was originally prepared as inflammatory cytokine synthesis inhibitor that subsequently was found to be selective inhibitor of p38 MAP kinase. SB-203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 uM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 uM. SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells. Development of SB-203580 for cancer; postmenopausal osteoporosis; rheumatoid arthritis; septic shock has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serine/threonine-protein kinase RAF 11	Inhibitor 8,504	2.0 µM [IC50]
MAP kinase p38 alpha 34	Inhibitor 8,504	48.0 nM [IC50]
MAP kinase p38 5	Inhibitor 8,504	37.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Cancer 609	Primary	Preclinical	Unknown
Rheumatoid arthritis 320	Primary	Preclinical	Unknown
Postmenopausal osteoporosis 59	Primary	Preclinical	Unknown

PubMed

Show entries

Title	Date	PubMed
Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro.	2000 Apr 1	10727428
Synergistic effect of diesel organic extracts and allergen Der p 1 on the release of chemokines by peripheral blood mononuclear cells from allergic subjects: involvement of the map kinase pathway.	2000 Aug	10919993
Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells.	2000 Aug 21	10952721
NF-kappa B regulates the LPS-induced expression of interleukin 12 p40 in murine peritoneal macrophages: roles of PKC, PKA, ERK, p38 MAPK, and proteasome.	2000 Aug 25	11006016
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen.	2000 Dec 8	10993886

Showing 1 to 5 of 50 entries

Previous1 2 3 4 5…10Next

Patents

Sample Use Guides

In Vivo Use Guide

four intraperitoneal injections of 5 mg/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

After treatment with SB-203580 (15 uM/L) 24 h and 48 h, the early and late apoptosis of MCF-7/Adr cells expressing the phosphorylated p38MAPK protein was (25.36 +/- 1.17)% and (38.21 +/- 1.25)%, respectively